Cellbricks’ Post

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said. We are innovative: We are inquisitive and resourceful. Each day we solve problems, think outside the box and push boundaries in the pursuit of delivering novel therapeutics. Our science is stellar, enabling us to not only identify the target but also understand how it interacts with its native ecosystem, separate from the confounding complexity of the cell. We do high-quality science on a daily basis! Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Follow this thread over the coming days to find out the 15 reasons OMass Therapeutics is Fierce!

Does your business have a winning commercialisation strategy? Stevenage Bioscience Catalyst are hosting two open evenings for their accelerator programme Catalyser - designed specifically for start-ups specialising in human health innovation who want to refine their commercialisation strategy. Take a look 👇

🚀 Momentum Biotechnologies 𝑎𝑛𝑑 Cube Biotech 𝐹𝑜𝑟𝑔𝑒 𝑺𝒕𝒓𝒂𝒕𝒆𝒈𝒊𝒄 𝑷𝒂𝒓𝒕𝒏𝒆𝒓𝒔𝒉𝒊𝒑 𝑡𝑜 𝐴𝑐𝑐𝑒𝑙𝑒𝑟𝑎𝑡𝑒 𝑵𝒆𝒙𝒕-𝑮𝒆𝒏𝒆𝒓𝒂𝒕𝒊𝒐𝒏 𝑫𝒓𝒖𝒈 𝑫𝒊𝒔𝒄𝒐𝒗𝒆𝒓𝒚🚀 Cube Biotech is deeply committed to overcoming the challenges of membrane protein research, and we’re thrilled to announce our strategic partnership with Momentum Biotechnologies to push the boundaries of drug discovery. This marks Cube Biotech’s second major collaboration, building on our successful partnership with NanoImaging Services to enhance the Cryo-EM gene-to-structure workflow. By combining Cube Biotech's pioneering platforms—designed to synthesize and purify complex membrane proteins preserving their native environment—and with Momentum's expertise in mass spectrometry-based drug discovery, we aim to accelerate the development of next-generation therapies. This collaboration empowers clients to tackle the challenging yet clinically crucial membrane protein targets with cutting-edge support. If your team is focused on membrane protein targets and you’re looking for innovative solutions, let’s connect! https://lnkd.in/gnd5Ew3P 👩🔬 🔬We’re here to turn your therapeutic visions into reality!!! 👨🔬 🔬 #DrugDiscovery #Biotechnology #MembraneProteins #MassSpectrometry #PharmaInnovation #LifeSciences

Watch now: Prescient Therapeutics’ CEO & MD Steven Yatomi-Clarke provides an update on our strategy and upcoming milestones 💡 https://hubs.ly/Q02qRymS0 Focusing on PTX-100, Steven discusses how the upcoming PTX-100 Phase 2 trials places the company at a major value inflection point. #Biotech #PTX100 #CellTherapies #CancerTherapies

Congratulations to Nuclera on securing $75 million in Series C financing! Nuclera, the Amadeus-backed biotechnology company revolutionising protein expression and purification workflows with its eProtein Discovery™ benchtop system, has successfully closed a $75 million financing round. This significant investment, led by Elevage Medical Technologies and supported by Patient Square Capital, British Patient Capital, and others, will accelerate the commercialization of Nuclera’s innovative platform. Dr. Michael Chen, CEO and co-founder of Nuclera, shared: “This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come.” Dr. Michael Wasserman, COO of Elevage Medical Technologies, added: “Nuclera has developed a solution for one of the leading obstacles in drug discovery: access to proteins that are needed throughout the drug discovery process. Elevage is proud to support Nuclera and its leadership team as it continues to bring the eProtein Discovery System to drug discovery researchers across the globe.” 🔗Read the full release here: https://bit.ly/48b0bQX #Nuclera #SeriesC #biotech #proteinexpression #drugdiscovery

Working with patient-derived cells. In the latest instalment of their three-part video series, we hear from the Inaphaea BioLabs team and collaborators as they speak about how they work with PDCs. #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #PDCs

Click the link below for the final video summary for this series (watch out for more later!) describing some of our work with Patient Derived Cells (PDCs). If this doesn’t give enough detail, then please reach out to any of our commercial team, Andrew Carnegie Mark Eccleston and Gareth Griffiths to discuss scientific and commercial details for your projects. #cancerresearch #innovation #inaphaea

Working with patient-derived cells. In the last of our three-part video series, we explain how our patient-derived cells are used in the area of drug discovery for our clients. Also, you will hear from our collaborators as they weigh in with their thoughts on PDCs. #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #PDCs

Earlier this week, Prof Alan Boyd had the pleasure of attending the 2-day Fierce Biotech Summit in Boston. A big thank you to the organizers at Fierce Pharma, and to the insightful speakers and panelists for leading some great discussions on the future of the biotech industry. 📧 If you didn't get the chance to connect with Alan at the Summit, or would like to learn more about how Boyds can support your path to drug approval, reach out at info@boydconsultants.com. Fierce Life Sciences Events #FierceBiotechSummit #BiotechInnovation #FierceBiotech #Biotech2024